Disrupting the Clinical Trial Ecosystem

It’s simple. No access to clinical trials means no treatment which means no outcomes. There’s a growing intensity and time consumption happening in clinical trials these days. If there were any lessons learned from the COVID-19 vaccine development process, it’s that we need diversity and speed to market to take hold of antiquated progress in introducing new treatments to the market. But how as clinical trial leaders do, we do this?

Expand Education on the Value of Clinical Trials

Clinical research is at the core of an educational process. Whether it’s prospective trial participants, physicians, or investors, we need to use our tools and technologies to break down barriers so that we can speak effectively to our target audiences.

Expand Access and Opportunity

We must bring clinical trials to the people and meet them where they are. Profound Research, connects patients and physicians to advanced therapeutic options through clinical research in their communities. The clinical trial success story of tomorrow means that participants can easily participate in clinical trials. Removing barriers to clinical trial participation must be a priority for advancements.

“Every day we accelerate a clinical trial is a better day for the patients receiving treatment” Kimberly Tableman, CEO/Founder, ESPERO

Consider Emerging Technologies

Connecting and integrating platforms and technologies is a way to accelerate the process of standardizing documentation. We must peel back the administrative burden. Taking more than 300 days to finalize a protocol is standing in the way of progress.

Keep the Human Aspect of Clinical Trials at the Forefront

People want relationships, not gift cards. By capturing the trust of the people who are participating in the trial, we create a win-win solution for all.

What’s Next?

At Halloran, our experienced team is ready to help you implement changes more efficiently, effectively, and sustainably. Our clinical trial leaders design forward-thinking yet executable clinical trial studies by tapping subject matter experts and strategic partnerships to ensure we create a bottom-up strategy – placing your clinical trial goals at the center of our thinking. Now as a part of ProductLife Group, we have access to hundreds of experts around the world ensuring your study design will align with regulatory requirements.

The contents of this blog are drawn from an on-site workshop, “Disrupting the Clinical Trial Ecosystem: Discovering New Players for New Opportunities,” held during Halloran’s CORE East program. More than 100 participants spent three days discussing clinical development approaches and best practices. Through the active exchange of ideas attendees shared valuable insights, applying them to their respective organizations. This event offers unparalleled access to industry leaders, decision-makers, and engaged participants who are passionate about life sciences and drug & device development. We thank Sheila Gwizdak, VP/Head of Consulting, Halloran Consulting Group; Matt Chapman Senior Director, Commercial Strategy, Profound Research; and Kimberly Tableman, CEO/Founder, ESPERO, for their contributions.

We thank our expert panel for their contributions. As you prepare for 2025 and beyond, we’re ready to help you achieve success. To learn more about our CORE program being planned for the fall 2025, be sure to contact us to be placed on the mailing list for invitation notification.